View in EDS

O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.

Saved in:
Bibliographic Details
Title: O-10 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.
Authors: Ilson, D.1, Moughan, J.2, Safran, H.3, Wigle, D.4, Depetrillo, T.3, Haddock, M.5, Hong, T.6, Leichman, L.7, Rajdev, L.8, Resnick, M.3, Kachnic, L.9, Seaward, S.10, Mamon, H.11, Pardo, D. Dian12, Anderson, C.13, Shen, X.14, Sharma, A.15, Katz, A.16, Salo, J.17, Leonard, K.3
Source: Annals of Oncology. 2020 Supplement 3, Vol. 31, p235-235. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2020.04.063